HomeCompareQSY vs MRK

QSY vs MRK: Dividend Comparison 2026

QSY yields 1.12% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $35.5K in total portfolio value
10 years
QSY
QSY
● Live price
1.12%
Share price
$63.37
Annual div
$0.71
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$120.31
Full QSY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — QSY vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQSYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QSY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QSY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QSY
Annual income on $10K today (after 15% tax)
$95.10/yr
After 10yr DRIP, annual income (after tax)
$102.26/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,226.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QSY + MRK for your $10,000?

QSY: 50%MRK: 50%
100% MRK50/50100% QSY
Portfolio after 10yr
$39.0K
Annual income
$4,959.22/yr
Blended yield
12.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

QSY
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QSY buys
1
MRK buys
0
PoliticianChamberTickerTypeAmountDate
Kevin Hern🏢 House$QSY▲ Buy$1,001 - $15,0002020-02-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQSYMRK
Forward yield1.12%2.76%
Annual dividend / share$0.71$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$21.3K$56.8K
Annual income after 10y$120.31$9,798.13
Total dividends collected$1.2K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QSY vs MRK ($10,000, DRIP)

YearQSY PortfolioQSY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,812$111.88$11,206$366.19$394.00MRK
2$11,682$113.05$12,650$502.35$968.00MRK
3$12,614$114.16$14,407$694.19$1.8KMRK
4$13,612$115.20$16,585$967.82$3.0KMRK
5$14,681$116.18$19,342$1,363.89$4.7KMRK
6$15,826$117.11$22,913$1,947.19$7.1KMRK
7$17,051$117.98$27,662$2,823.89$10.6KMRK
8$18,364$118.81$34,159$4,173.35$15.8KMRK
9$19,769$119.58$43,337$6,308.80$23.6KMRK
10$21,273$120.31$56,776$9,798.13$35.5KMRK

QSY vs MRK: Complete Analysis 2026

QSYStock

The fund, an exchange traded fund, is actively managed using a model-based approach. It seeks to achieve its investment objective by investing primarily in U.S. equity securities that provide a high "total shareholder yield" and exhibit favorable quality characteristics that demonstrate a company's profitability, such as strong ROE and/or ROA. The fund invests primarily in equity securities of companies domiciled in the U.S. or listed on a U.S. exchange. The advisor generally expects to invest in large- and mid-capitalization companies and may invest in any sector. The fund is non-diversified.

Full QSY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this QSY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QSY vs SCHDQSY vs JEPIQSY vs OQSY vs KOQSY vs MAINQSY vs JNJQSY vs ABBVQSY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.